# EDGAR Filing Document

**Accession Number:** 0001131343
**File Stem:** 0001213900-25-087423
**Filing Date:** 2025-9
**Character Count:** 5072
**Document Hash:** 90658a1788324017e260e079aa6d06b4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-087423.hdr.sgml**: 20250915

**ACCESSION NUMBER**: 0001213900-25-087423

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250915

**FILED AS OF DATE**: 20250915

**DATE AS OF CHANGE**: 20250915

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALTERITY THERAPEUTICS LTD
- **CENTRAL INDEX KEY:** 0001131343
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-49843
- **FILM NUMBER:** 251313217

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 460 BOURKE STREET
- **CITY:** MELBOURNE
- **PROVINCE COUNTRY:** C3
- **BUSINESS PHONE:** 61 3 9349 4906

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 460 BOURKE STREET
- **CITY:** MELBOURNE
- **PROVINCE COUNTRY:** C3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRANA BIOTECHNOLOGY LTD
- **DATE OF NAME CHANGE:** 20010105

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-163**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of September 2025**

**Alterity Therapeutics Limited**

(Name of Registrant)

**Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia**

(Address of Principal Executive Office)

**Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.**

Form 20-F ☒ Form 40-F ☐

**This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. [333-251073](http://www.sec.gov/Archives/edgar/data/1131343/000121390020040485/ea130838-s8_alteritytherape.htm), [333-248980](http://www.sec.gov/Archives/edgar/data/1131343/000121390020027969/ea127207-s8_alteritytherap.htm) and [333-228671](http://www.sec.gov/Archives/edgar/data/1131343/000114420418063081/tv508429_s-8.htm)) and our Registration Statements on Form F-3 (Files No. [333-274816](http://www.sec.gov/Archives/edgar/data/1131343/000101376223000033/ea185947-f3_alteritytherape.htm), [333-251647](http://www.sec.gov/Archives/edgar/data/1131343/000121390020044324/ea132148-f3_alteritytherape.htm), [333-231417](http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_f3.htm) and [333-250076](http://www.sec.gov/Archives/edgar/data/1131343/000121390020036934/ea129831-f3_alteritytherap.htm))**

**ALTERITY THERAPEUTICS LIMITED**

**(a development stage enterprise)**

The following exhibits are submitted:

99.1 [Notice Under Section 708A](ea025733201ex99-1_alterity.htm)

**<u>SIGNATURE</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Alterity Therapeutics Limited** | **Alterity Therapeutics Limited** |
| By: | /s/ Geoffrey P. Kempler |
|  | Geoffrey P. Kempler |
|  | Chairman |

---

Date: September 15, 2025

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

---

| | |
|:---|:---|
| **ASX ANNOUNCEMENT** | 15 September 2025 |

---

**Notice Under Section 708A(5)(e) of the Corporations Act**

This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Details of securities issued** | &nbsp;&nbsp;**Details of securities issued** |
| &nbsp;&nbsp;**Type:** | &nbsp;&nbsp;**Shares** |
| &nbsp;&nbsp;Class/Description: | &nbsp;&nbsp;Fully paid ordinary shares |
| &nbsp;&nbsp;ASX Code: | &nbsp;&nbsp;ATH |
| &nbsp;&nbsp;Date of Issue: | &nbsp;&nbsp;15 September 2025 |
| &nbsp;&nbsp;Number Issued: | &nbsp;&nbsp;1666666663 |

---

The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act that:

&nbsp;&nbsp;&nbsp;&nbsp;1. the Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act;

&nbsp;&nbsp;&nbsp;&nbsp;2. as at the date of this notice, the Company has complied with:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) sections 674 and 674A of the Corporations Act; and

&nbsp;&nbsp;&nbsp;&nbsp;3. as at the date of this notice there is no information to be disclosed which is 'excluded information'
(as defined in sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by the Company.

**Abby Macnish Niven**

**Company Secretary**

Alterity Therapeutics Limited ACN 080 699 065

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

www.alteritytherapeutics.com